A secretome profiling confirmed the ability of silibinin to normalize the augmented release of TGFβ into the extracellular fluid of ALK–TKIs-resistant NSCLC cells while significantly reducing constitutive and inducible SMAD2/3 phosphorylation in the presence of ALK–TKIs. This evidence concerns the gene SMAD2 and non-small cell lung carcinoma.